Pharmaceutical

Filter

Current filters:

None

Popular Filters

1 to 25 of 7177 results

FDA approves Alcon’s Xtoro to treat swimmer’s ear

18-12-2014

The US Food and Drug Administration today approved Xtoro (finafloxacin otic suspension), a new drug used…

Acute otitis externaAlcon LaboratoriesAntibiotics and Infectious diseasesHealthNovartisPharmaceuticalRegulationUSAXtoro

Insulin therapeutics specialist Nutrinia completes $12 million financing round

Insulin therapeutics specialist Nutrinia completes $12 million financing round

18-12-2014

Nutrinia, a developer of oral insulin therapies to treat rare gastrointestinal disorders in babies, has…

Business FinanceEndocrine systemGastro-intestinalsNutriniaPharmaceutical

Eisai's Halaven now available in Russia for advanced breast cancer

Eisai's Halaven now available in Russia for advanced breast cancer

18-12-2014

Halaven (eribulin) manufactured by Japanese drug major Eisai is now available in Russia.

EisaiHalavenOncologyPharmaceuticalRegulationRussia

Lundbeck to stop further development of desmoteplase

Lundbeck to stop further development of desmoteplase

18-12-2014

Following evaluation of disappointing clinical results, Danish CNS specialists Lundbeck said late yesterday…

Cardio-vasculardesmoteplaseFinancialLundbeckNeurologicalPharmaceuticalResearch

Auspex leaps on positive results from Phase III trial of SD-809 in Huntington's chorea

Auspex leaps on positive results from Phase III trial of SD-809 in Huntington's chorea

17-12-2014

Movement disorder biopharma specialist Auspex Pharmaceuticals announced positive top-line data from its…

Auspex PharmaceuticalsNeurologicalPharmaceuticalResearchSD-809USA

Strong top-line results for Poxel’s antidiabetic agent imeglimin

Strong top-line results for Poxel’s antidiabetic agent imeglimin

17-12-2014

France-based drug developer Poxel says that imeglimin, a novel compound in development to treat type…

DiabetesFranceHealthimegliminMerck SeronoPharmaceuticalPoxelResearch

KCR acquires project portfolio from Ukraine’s CRO AXIS

KCR acquires project portfolio from Ukraine’s CRO AXIS

17-12-2014

KCR, a Poland-based contract research organization (CRO), has recently acquired the whole portfolio of…

AXIS GroupKCRMergers & AcquisitionsPharmaceuticalResearchUkraine

Ipsen appoints François Garnier as executive vice president, general counsel

Ipsen appoints François Garnier as executive vice president, general counsel

17-12-2014

French drugmaker Ipsen has appointed François Garnier as executive vice president, general counsel of…

BoardroomFranceIpsenIpsen GroupPharmaceutical

New guidance provides optimism for securing life sciences patents in USA

New guidance provides optimism for securing life sciences patents in USA

17-12-2014

The US Patent and Trademark Office (USPTO) has released its 2014 Interim Guidance on Patent Subject Matter…

PatentsPharmaceuticalPrometheus LabsUS Patent and Trademark OfficeUSA

FDA approves Ipsen's Somatuline for metastatic gastroentero pancreatic neuroendocrine tumors

FDA approves Ipsen's Somatuline for metastatic gastroentero pancreatic neuroendocrine tumors

17-12-2014

The US Food and Drug Administration has approved Somatuline Depot (lanreotide) injection 120mg, manufactured…

IpsenOncologyPharmaceuticalRegulationSomatulineUSA

Top 30 Pharmas spent $112 billion on R&D in 2013; report

Top 30 Pharmas spent $112 billion on R&D in 2013; report

17-12-2014

The world’s leading 30 pharmaceutical companies spent a combined $112 billion on research and development…

FinancialGlobalGlobalDataJohnson & JohnsonNovartisPfizerPharmaceuticalPharmaceutical sciencesResearch

Janssen returns rights of IBD drug GLPG1205 to Galapagos

Janssen returns rights of IBD drug GLPG1205 to Galapagos

17-12-2014

US health care giant Johnson & Johnson’s Europe-based subsidiary Janssen has returned the rights to…

GalapagosGastro-intestinalsJanssenJanssen PharmaceuticaLicensingPharmaceutical

Cyclacel shares fall as sapacitabine disappoints in Phase III acute myeloid leukemia trial

Cyclacel shares fall as sapacitabine disappoints in Phase III acute myeloid leukemia trial

17-12-2014

The announcement that Cyclacel Pharmaceuticals’ (Nasdaq: CYCC) Phase III trial of sapacitabine was…

CyclacelOncologyPharmaceuticalResearchsapacitabine

New drug price cuts demonstrate Australian PBS sustainability

New drug price cuts demonstrate Australian PBS sustainability

17-12-2014

In Australia, price cuts to over 100 Pharmaceutical Benefits Scheme (PBS)-listed medicines that will…

AustraliaAustralian PBSHealthcarePharmaceuticalPricing

NICE backs Pradaxa for treating and preventing potentially fatal blood clots

NICE backs Pradaxa for treating and preventing potentially fatal blood clots

17-12-2014

In final guidance published today, UK health cost watchdog the National Institute for Health and Care…

Boehringer IngelheimCardio-vascularPharmaceuticalPradaxaPricingRegulationUK

Lightlake in deal with Adapt Pharma subsidiary

16-12-2014

UK biopharma firm Lightlake Therapeutics has entered into a license agreement with Adapt Pharma Operations,…

Adapt PharmaLicensingLightlake TherapeuticsNaloxoneNeurologicalPharmaceutical

Trade groups call for integrated life science strategy ahead of European Commission Work Program

Trade groups call for integrated life science strategy ahead of European Commission Work Program

16-12-2014

European research and generic/biosimilar industry associatins have called for an integrated life science…

Advocacy groupsCompetitivenessEuropePharmaceuticalRegulation

Novartis gains US FDA approval of Signifor for acromegaly

Novartis gains US FDA approval of Signifor for acromegaly

16-12-2014

The US Food and Drug Administration has approved Swiss pharma giant Novartis’ Signifor (pasireotide)…

NovartisPharmaceuticalRare diseasesRegulationSigniforUSA

UK’s NICE recommends Pfizer’s Inlyta for kidney cancer

UK’s NICE recommends Pfizer’s Inlyta for kidney cancer

16-12-2014

UK health costs watchdog the National Institute for Health and Care Excellence (NICE) has issued new…

InlytaOncologyPfizerPharmaceuticalPricingRegulationUK

Added benefit of Eylea over Lucentis in DME not proven, says IQWiG

Added benefit of Eylea over Lucentis in DME not proven, says IQWiG

16-12-2014

The German Institute for Quality and Efficiency in Health Care (IQWiG) has compared trial data on German…

BayerEyleaGermanyLucentisNovartisOphthalmicsPharmaceuticalPricingRegulationRoche

UK NICE partially backs Bayer’s Xofigo in preliminary assessment

UK NICE partially backs Bayer’s Xofigo in preliminary assessment

15-12-2014

UK health costs watchdog the National Institute for Health and Care Excellence (NICE) have recommended…

BayerOncologyPharmaceuticalPricingRegulationUKXofigo

1 to 25 of 7177 results

Back to top